<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-18291" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Biologic Response Modifiers (BRMs)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sapkota</surname>
            <given-names>Binita</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Makandar</surname>
            <given-names>Shah N.</given-names>
          </name>
          <aff>Rajiv Gandhi University of Health Sci.</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Acharya</surname>
            <given-names>Saurav</given-names>
          </name>
          <aff>University of Tennessee HSC</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Binita Sapkota declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shah Makandar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Saurav Acharya declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-18291.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Biologic response modifiers (BRMs), also known as immunomodulators, are the class of medications that target the disease-causing mechanism. They are used in autoimmune diseases as first-line medications or after the failure of conventional agents. Serious infections are the most feared complications and require screening before initiation, and monitoring while patients are taking the medications. This activity reviews the evaluation and management of various autoimmune conditions with the use of BRMs and highlights the role of the interprofessional team in evaluating and treating patients with these medications.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the indications for biologic response modifiers.</p></list-item><list-item><p>Identify the adverse events associated with biologic response modifiers.</p></list-item><list-item><p>Review the importance of monitoring patients taking biologic response modifiers.</p></list-item><list-item><p>Explain the importance of improving care coordination among the interprofessional team to improve outcomes for patients receiving biologic response modifiers.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18291&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18291">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-18291.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Biologic response modifiers (BRMs), also known as immunomodulators or cytokine inhibitors, are naturally occurring substances in our body that can also be manufactured in the laboratory. Autoimmune diseases incur a substantial economic burden to the patients and society.&#x000a0;BRMs target the disease-causing mechanism and have now become revolutionary in the treatment of many autoimmune phenomena. Unsatisfactory response or evidence of disease progression despite treatment with conventional therapy mandates the use of BRM alone or in combination with traditional treatment.<xref ref-type="bibr" rid="article-18291.r1">[1]</xref> For example, tumor necrosis factor (TNF) inhibitors, in conjunction with methotrexate, were superior to either methotrexate or a TNF inhibitor alone in patients with rheumatoid arthritis (RA) resistant to initial therapy.<xref ref-type="bibr" rid="article-18291.r2">[2]</xref>&#x000a0;A combination of a biologic agent and an immunomodulator is commonly used to induce and maintain remission in patients with moderate to severe Crohn disease.<xref ref-type="bibr" rid="article-18291.r3">[3]</xref> BRMs are also recommended first-line therapy for severe psoriatic arthritis who already have erosive changes, and axial involvement in the form of sacroilitis or spondylitis. Patients with axial ankylosing spondylitis (AS) who have very high disease activity, defined as a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) more than or equal to four and patients with peripheral AS with concomitant moderate to severe psoriasis, inflammatory bowel disease or flares of anterior uveitis also benefit from BRMs.<xref ref-type="bibr" rid="article-18291.r4">[4]</xref> Anakinra used as initial therapy in patients with systemic juvenile idiopathic arthritis (JIA) resulted in rapid symptom relief and also prevented chronic arthritis.<xref ref-type="bibr" rid="article-18291.r5">[5]</xref>&#x000a0;</p>
        <p>Knowing the fact that TNF-alpha, interleukin (IL)-17, IL-1 are vital mediators of graft versus host disease,<xref ref-type="bibr" rid="article-18291.r6">[6]</xref> BRMs have been used to prevent and treat GVHD.<xref ref-type="bibr" rid="article-18291.r7">[7]</xref>&#x000a0;BRMs are also therapeutic in various cancers of the lung, head, neck, skin, kidneys, bladder, and hematologic malignancies. Biologics targeting programmed cell death protein (PD-1), e.g., pembrolizumab and nivolumab, have been emerging as a newer treatment modality for melanoma, renal cell cancer, non-squamous lung cancer, lymphoma, and gastrointestinal cancers.<xref ref-type="bibr" rid="article-18291.r8">[8]</xref>&#x000a0;BRMs are also found to be effective in secondary amyloidosis in patients with RA and AS.<xref ref-type="bibr" rid="article-18291.r9">[9]</xref> Biologics targeting IL-5 have been emerging in the treatment of severe hypereosinophilic asthma.<xref ref-type="bibr" rid="article-18291.r10">[10]</xref></p>
        <p>TNF inhibitors, e.g., infliximab, etanercept, adalimumab, certolizumab, and golimumab has been FDA approved for use in RA, ulcerative colitis (UC), Crohn disease (CD), AS, JIA, plaque psoriasis and, psoriatic arthritis. Adalimumab also has approval for hidradenitis suppurativa and uveitis. Non-FDA-approved indications include pyoderma gangrenosum, pustular psoriasis, and GVHD(etanercept). Interleukin-1 inhibitor, e.g., anakinra, is FDA approved for RA and neonatal-onset multisystem inflammatory disease. IL-2 inhibitor, e.g., aldesleukin, is used in metastatic renal cell carcinoma and melanoma. Tocilizumab is an interleukin-6 inhibitor used in giant cell arteritis, JIA, and RA. Secukinumab that targets interleukin-17 is FDA approved for psoriasis (plaque and arthritis), and AS. Ustekinumab blocks interleukin 12/23 and has been FDA-approved for plaque psoriasis, psoriatic arthritis, and CD. Abatacept (T-cell co-stimulation blocker) has approval for use in RA, JIA, and Psoriatic arthritis. Rituximab is FDA approved for chronic lymphocytic leukemia, non-Hodgkins lymphoma, RA, granulomatous polyangiitis, and pemphigus vulgaris. Off label uses include Burkitt lymphoma, CNS lymphoma, GVHD, lupus nephritis, and Hodgkin lymphoma. Tofacitinib is Janus kinase (JAK) inhibitors indicated for psoriatic arthritis, RA, and UC.<xref ref-type="bibr" rid="article-18291.r11">[11]</xref></p>
      </sec>
      <sec id="article-18291.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>CD4-T cells can differentiate into T helper cells Th1 and Th2. Th1 cells participate in cell-mediated inflammation by producing interferon-gamma, TNF, and IL 2 that target intracellular pathogens. Th2 cells participate in humoral immunity that stimulates antibody production by B cells to produce IL-4, IL-5, IL-10, and IL-13 that target extracellular pathogens. These cytokines are involved in the mediation of inflammatory response, infection, autoimmunity, transplant rejection, and GVHD.<xref ref-type="bibr" rid="article-18291.r12">[12]</xref> Biologic response modifiers modulate the immune response by either interfering with the effect of these cytokines,<xref ref-type="bibr" rid="article-18291.r13">[13]</xref> inhibiting the costimulation of T cell activation,<xref ref-type="bibr" rid="article-18291.r14">[14]</xref> depleting/inhibiting B cells.<xref ref-type="bibr" rid="article-18291.r15">[15]</xref> JAK inhibitors target at the intracellular level by blocking the cellular signaling pathway.&#x000a0;</p>
      </sec>
      <sec id="article-18291.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Biologic response modifier therapy is administered either by intravenous (IV) or subcutaneous (SC) route. IV is usually done in the hospital or outpatient setting, while SC is generally self-administered by patients or by health care professionals.<xref ref-type="bibr" rid="article-18291.r16">[16]</xref>&#x000a0;The administration could be weekly, biweekly, monthly, or bimonthly depending on the indication and half-life of the medication. Infliximab, sarilumab, tocilizumab, secukinumab, rituximab, and abatacept administration is intravenous. Adalimumab, golimumab, etanercept, certolizumab, anakinra, and ustekinumab administration is subcutaneous. Administration of batacept, tocilizumab, and golimumab can be either SC or IV, and tofacitinib dosing is oral.<xref ref-type="bibr" rid="article-18291.r17">[17]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-18291.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The adverse effects of biologic response modifier therapy could be secondary to stimulation, suppression, or disruption of immune homeostasis.<xref ref-type="bibr" rid="article-18291.r18">[18]</xref>&#x000a0;Immune stimulation causing activation of various immune cells including macrophages, monocytes, lymphocytes and natural killer cells leads to massive release of cytokines including IL1, TNF alfa, INF gamma, IL 6 and IL 8 that often cause symptoms such as fever, chills, muscle aches, weakness, loss of appetite, nausea, vomiting, diarrhea and skin rash.<xref ref-type="bibr" rid="article-18291.r19">[19]</xref>&#x000a0;</p>
        <p>Since T cell-mediated response is involved in the destruction of pathogens, inhibition of immune response by BRM increases the risk of asymptomatic to life-threatening infection due to the virus, bacteria, mycobacteria, fungi, and protozoa.<xref ref-type="bibr" rid="article-18291.r20">[20]</xref><xref ref-type="bibr" rid="article-18291.r21">[21]</xref>&#x000a0;Infection risk is increased, notably in patients with advanced diseases and those who already have received treatment with other immunosuppressants. Infections include reactivation of hepatitis B, hepatitis C, <italic toggle="yes">Mycobacterium tuberculosis</italic> (TB), non-mycobacterial TB, <italic toggle="yes">Histoplasma</italic>, <italic toggle="yes">Cryptococcus</italic>, <italic toggle="yes">Coccidioides</italic>, <italic toggle="yes">Blastomyces</italic>, Pulmonary actinomycosis,<xref ref-type="bibr" rid="article-18291.r22">[22]</xref>
<italic toggle="yes">Pneumocystis carinii</italic>,<xref ref-type="bibr" rid="article-18291.r23">[23]</xref> and CMV. There are reports of infections due to the West Nile virus, parvovirus B19, influenza, herpes simplex, VZV, <italic toggle="yes">Aspergillus</italic>, <italic toggle="yes">Candida</italic>, <italic toggle="yes">Listeria</italic>, <italic toggle="yes">Streptococcus pneumoniae</italic>.<xref ref-type="bibr" rid="article-18291.r24">[24]</xref><xref ref-type="bibr" rid="article-18291.r25">[25]</xref>&#x000a0;Though severe infection often leads to discontinuation of the drug, the rate of serious infections has been declining recently, likely due to increased vigilance and surveillance associated with the use of these medications.<xref ref-type="bibr" rid="article-18291.r26">[26]</xref><xref ref-type="bibr" rid="article-18291.r27">[27]</xref> The frequency of adverse events with each of these medications has been observed to be disease-specific. For example, researchers noted that the treatment of AS with TNF inhibitors was associated with a lower rate of serious adverse events compared to the treatment of RA. It could be explainable by the fact that RA in itself causes immunosuppression, and treatment is often in combination with other DMARD or steroids.<xref ref-type="bibr" rid="article-18291.r28">[28]</xref>&#x000a0;</p>
        <p>Several biologics also increase the risk of malignancies, such as Hodgkin and non-Hodgkin lymphoma, leukemia, non-melanoma skin cancer.<xref ref-type="bibr" rid="article-18291.r29">[29]</xref></p>
        <p>Disruption of immune homeostasis causes a paradoxical effect in various tissues leading to autoimmunity. Various BRM has associations with a lupus-like syndrome, antiphospholipid syndrome, vasculitis, dermatomyositis, polymyositis, peripheral neuropathy, multiple sclerosis, autoimmune hepatitis, optic neuritis, uveitis, and interstitial lung disease.<xref ref-type="bibr" rid="article-18291.r30">[30]</xref>&#x000a0;TNF inhibitors used to treat certain autoimmune diseases was found to exacerbate inflammatory bowel disease,<xref ref-type="bibr" rid="article-18291.r31">[31]</xref> sarcoidosis-like lesions and psoriasis.<xref ref-type="bibr" rid="article-18291.r32">[32]</xref><xref ref-type="bibr" rid="article-18291.r33">[33]</xref>&#x000a0;Adalimumab was found to be associated with multiple sclerosis.<xref ref-type="bibr" rid="article-18291.r34">[34]</xref> BRM molecules can also act as an antigen for preformed antibodies in the body, causing anaphylactic reactions.<xref ref-type="bibr" rid="article-18291.r18">[18]</xref> Additionally, infusion reaction can manifest as fever, urticaria, hypotension, and angioedema due to acute hypersensitivity reaction or polyarthritis, and rash due to a delayed hypersensitivity reaction.<xref ref-type="bibr" rid="article-18291.r35">[35]</xref> Injection site reactions manifest as redness, pain, swelling, cutaneous infection, bruising, and itching.<xref ref-type="bibr" rid="article-18291.r36">[36]</xref></p>
      </sec>
      <sec id="article-18291.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Biologic response modifiers should not be taken by patients who have active infections, demyelinating diseases, e.g., (multiple sclerosis, optic neuritis), and immunodeficiency syndromes. The use of TNF alfa blockers in chronic granulomatous disease-associated colitis was found to increase rates of severe infections and even mortality.<xref ref-type="bibr" rid="article-18291.r37">[37]</xref>&#x000a0;</p>
        <p>BRM should also be avoided in patients with chronic recurrent infections and untreated latent TB. TNF inhibitors should be avoided or used with caution in a patient with CHF.<xref ref-type="bibr" rid="article-18291.r38">[38]</xref>&#x000a0;Evidence is limited for safety during pregnancy and breastfeeding. It is advised to avoid pregnancy or breastfeeding while taking BRMs.<xref ref-type="bibr" rid="article-18291.r39">[39]</xref></p>
      </sec>
      <sec id="article-18291.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Before starting biologic response modifier therapy, patients should undergo evaluation for latent TB with the past medical history of TB, tuberculin skin test, chest X-ray, and TB interferon. Latent TB should have treatment for nine months, and treatment with BRM can be started one month after the treatment initiation.&#x000a0;This approach has demonstrated to decrease the rate of reactivation of TB.<xref ref-type="bibr" rid="article-18291.r40">[40]</xref> For active TB infection, treatment with BRM should be started only often completion of treatment for TB. Hepatitis B surface Antigen test, liver function test (LFT), complete blood count (CBC), age-appropriate screening for cancer, pregnancy test, monitoring for contraindications and drug interactions should be done. Age-appropriate vaccine status should be updated, e.g., pneumococcal, influenza, and hepatitis B vaccinations.<xref ref-type="bibr" rid="article-18291.r41">[41]</xref> The live vaccine should be given at least four weeks before BRM treatment.</p>
        <p>All patients taking BRM should have monitoring for both treatment-related efficacy and safety. The patient's symptom relief, physical exam, erythrocyte sedimentation rate, C-reactive protein, autoimmune markers, radiography, CBC, and LFT can be used to monitor efficacy and safety.<xref ref-type="bibr" rid="article-18291.r42">[42]</xref> Treatment should stop if there is no evidence of effectiveness within 3 to 6 months of therapy or any evidence of severe side effects or pregnancy. Due to concern for risks of infection, many experts recommend stopping BRMs at least two half-life of particular medication before surgery and resume once wound healing, and no evidence of infection is ensured usually after 1 to 2 weeks.<xref ref-type="bibr" rid="article-18291.r43">[43]</xref></p>
      </sec>
      <sec id="article-18291.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Biologic response modifiers can often cause bone marrow suppression, hepatotoxicity, cardiopulmonary and renal dysfunction, disseminated intravascular coagulation, and often death. Toxicity is usually due to immune system activation and is manageable by premedication or adjusting dose.<xref ref-type="bibr" rid="article-18291.r44">[44]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-18291.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Early treatment with a biologic response modifier improves outcomes and prevents disability related to autoimmune diseases; however, currently, no clinical predictors or biomarkers are available to guide physicians to select BRM for an individual patient. Not all patients with the same illness respond to particular BRM. Genetic polymorphism in the genes encoding the receptors that the BRM targets affect the efficacy of BRM. Performing genetic tests before starting the treatment may help in choosing a specific BRM for a particular patient.</p>
        <p>It is crucial to consider patient-related factors, e.g., patient convenience, local availability, patient's understanding of risks of medication, route, the frequency of administration, and cost-effectiveness while choosing BRM. The patient should be actively involved while choosing and making a treatment decision, and they should be aware of the adverse effects of the medication under consideration.</p>
        <p>Nursing can help the patient with administration instructions and a discussion about possible side effects. The pharmacist must verify the dosing of the agent, check for drug-drug interactions, and also counsel the patient on signs of potential adverse effects. Nursing and pharmacy both need to have an open line of communication with the prescriber to adjust treatment if necessary.</p>
        <p>BRM therapy requires an interprofessional team approach, including physicians, specialists, specialty-trained nurses, and pharmacists, all collaborating across disciplines to achieve optimal patient results. [Level V]</p>
      </sec>
      <sec id="article-18291.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18291&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18291">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/18291/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=18291">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-18291.s11">
        <title>References</title>
        <ref id="article-18291.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Hossain</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tanjong Ghogomu</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mudano</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Tugwell</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>GA</given-names>
              </name>
            </person-group>
            <article-title>Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2016</year>
            <month>Nov</month>
            <day>17</day>
            <volume>11</volume>
            <issue>11</issue>
            <fpage>CD012437</fpage>
            <pub-id pub-id-type="pmid">27855242</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18291.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferraccioli</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>[Biologic therapy with anti-TNF&#x003b1; in rheumathoid arthritis].</article-title>
            <source>Reumatismo</source>
            <year>2005</year>
            <volume>57</volume>
            <issue>4 Suppl</issue>
            <fpage>17</fpage>
            <page-range>17-21</page-range>
            <pub-id pub-id-type="pmid">16385351</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18291.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>D'Haens</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Baert</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>van Assche</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Caenepeel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vergauwe</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tuynman</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>De Vos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van Deventer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stitt</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Donner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vermeire</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Van De Mierop</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Coche</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>van der Woude</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ochsenk&#x000fc;hn</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>van Bodegraven</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Van Hootegem</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Lambrecht</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Mana</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rutgeerts</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Feagan</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Hommes</surname>
                <given-names>D</given-names>
              </name>
              <collab>Belgian Inflammatory Bowel Disease Research Group</collab>
              <collab>North-Holland Gut Club</collab>
            </person-group>
            <article-title>Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.</article-title>
            <source>Lancet</source>
            <year>2008</year>
            <month>Feb</month>
            <day>23</day>
            <volume>371</volume>
            <issue>9613</issue>
            <fpage>660</fpage>
            <page-range>660-667</page-range>
            <pub-id pub-id-type="pmid">18295023</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18291.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ward</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Deodhar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Akl</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Lui</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ermann</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gensler</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Borenstein</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hiratzka</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Inman</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Majithia</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Haroon</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Maksymowych</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Joyce</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Colbert</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Figgie</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Hallegua</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Prete</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Rosenbaum</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Stebulis</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>van den Bosch</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Reveille</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Caplan</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.</article-title>
            <source>Arthritis Rheumatol</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>68</volume>
            <issue>2</issue>
            <fpage>282</fpage>
            <page-range>282-98</page-range>
            <pub-id pub-id-type="pmid">26401991</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18291.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nigrovic</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Mannion</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Prince</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Zeft</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rabinovich</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>van Rossum</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Cortis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pardeo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Miettunen</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Janow</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Birmingham</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Eggebeen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Janssen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Shulman</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Son</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ilowite</surname>
                <given-names>NT</given-names>
              </name>
              <name>
                <surname>Cron</surname>
                <given-names>RQ</given-names>
              </name>
              <name>
                <surname>Higgins</surname>
                <given-names>GC</given-names>
              </name>
            </person-group>
            <article-title>Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series.</article-title>
            <source>Arthritis Rheum</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>63</volume>
            <issue>2</issue>
            <fpage>545</fpage>
            <page-range>545-55</page-range>
            <pub-id pub-id-type="pmid">21280009</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18291.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>H&#x000fc;lsd&#x000fc;nker</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zeiser</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Insights into the pathogenesis of GvHD: what mice can teach us about man.</article-title>
            <source>Tissue Antigens</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>85</volume>
            <issue>1</issue>
            <fpage>2</fpage>
            <page-range>2-9</page-range>
            <pub-id pub-id-type="pmid">25532439</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18291.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cutler</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Antin</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Novel drugs for the prevention and treatment of acute GVHD.</article-title>
            <source>Curr Pharm Des</source>
            <year>2008</year>
            <volume>14</volume>
            <issue>20</issue>
            <fpage>1962</fpage>
            <page-range>1962-73</page-range>
            <pub-id pub-id-type="pmid">18691107</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18291.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Voena</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chiarle</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Advances in cancer immunology and cancer immunotherapy.</article-title>
            <source>Discov Med</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>21</volume>
            <issue>114</issue>
            <fpage>125</fpage>
            <page-range>125-33</page-range>
            <pub-id pub-id-type="pmid">27011048</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18291.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pamuk</surname>
                <given-names>&#x000d6;N</given-names>
              </name>
              <name>
                <surname>Kalyoncu</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Aksu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Omma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pehlivan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>&#x000c7;a&#x0011f;atay</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>K&#x000fc;&#x000e7;&#x000fc;k&#x0015f;ahin</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>D&#x000f6;nmez</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>&#x000c7;etin</surname>
                <given-names>GY</given-names>
              </name>
              <name>
                <surname>Mercan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bay&#x00131;nd&#x00131;r</surname>
                <given-names>&#x000d6;</given-names>
              </name>
              <name>
                <surname>&#x000c7;efle</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Y&#x00131;ld&#x00131;z</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Balkarl&#x00131;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>K&#x00131;l&#x00131;&#x000e7;</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>&#x000c7;ak&#x00131;r</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>K&#x00131;sac&#x00131;k</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>&#x000d6;ks&#x000fc;z</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>&#x000c7;obankara</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Onat</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Sayarl&#x00131;o&#x0011f;lu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>&#x000d6;zt&#x000fc;rk</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Pamuk</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Akko&#x000e7;</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>A multicenter report of biologic agents for the treatment of secondary amyloidosis in Turkish rheumatoid arthritis and ankylosing spondylitis patients.</article-title>
            <source>Rheumatol Int</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>36</volume>
            <issue>7</issue>
            <fpage>945</fpage>
            <page-range>945-53</page-range>
            <pub-id pub-id-type="pmid">27221456</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18291.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mukherjee</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sehmi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nair</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Anti-IL5 therapy for asthma and beyond.</article-title>
            <source>World Allergy Organ J</source>
            <year>2014</year>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>32</fpage>
            <pub-id pub-id-type="pmid">25709744</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18291.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davis</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Ballas</surname>
                <given-names>ZK</given-names>
              </name>
            </person-group>
            <article-title>Biologic response modifiers: Indications, implications, and insights.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>2017</year>
            <month>May</month>
            <volume>139</volume>
            <issue>5</issue>
            <fpage>1445</fpage>
            <page-range>1445-1456</page-range>
            <pub-id pub-id-type="pmid">28263774</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18291.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mosmann</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>KW</given-names>
              </name>
            </person-group>
            <article-title>The role of IL-10 in crossregulation of TH1 and TH2 responses.</article-title>
            <source>Immunol Today</source>
            <year>1991</year>
            <month>Mar</month>
            <volume>12</volume>
            <issue>3</issue>
            <fpage>A49</fpage>
            <page-range>A49-53</page-range>
            <pub-id pub-id-type="pmid">1648926</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18291.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bendtzen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Poulsen</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Svenson</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Cytokines and autoantibodies to cytokines.</article-title>
            <source>Stem Cells</source>
            <year>1995</year>
            <month>May</month>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>206</fpage>
            <page-range>206-22</page-range>
            <pub-id pub-id-type="pmid">7613489</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18291.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dilek</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Poirier</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hulin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Coulon</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mary</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ville</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vie</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cl&#x000e9;menceau</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Blancho</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vanhove</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Targeting CD28, CTLA-4 and PD-L1 costimulation differentially controls immune synapses and function of human regulatory and conventional T-cells.</article-title>
            <source>PLoS One</source>
            <year>2013</year>
            <volume>8</volume>
            <issue>12</issue>
            <fpage>e83139</fpage>
            <pub-id pub-id-type="pmid">24376655</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18291.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rein</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mueller</surname>
                <given-names>RB</given-names>
              </name>
            </person-group>
            <article-title>Treatment with Biologicals in Rheumatoid Arthritis: An Overview.</article-title>
            <source>Rheumatol Ther</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>4</volume>
            <issue>2</issue>
            <fpage>247</fpage>
            <page-range>247-261</page-range>
            <pub-id pub-id-type="pmid">28831712</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18291.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anselmo</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Gokarn</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mitragotri</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Non-invasive delivery strategies for biologics.</article-title>
            <source>Nat Rev Drug Discov</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>19</fpage>
            <page-range>19-40</page-range>
            <pub-id pub-id-type="pmid">30498202</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18291.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dowty</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ryder</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Vaz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Krishnaswami</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Prakash</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans.</article-title>
            <source>Drug Metab Dispos</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>42</volume>
            <issue>4</issue>
            <fpage>759</fpage>
            <page-range>759-73</page-range>
            <pub-id pub-id-type="pmid">24464803</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18291.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Descotes</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Immunotoxicity of monoclonal antibodies.</article-title>
            <source>MAbs</source>
            <year>2009</year>
            <season>Mar-Apr</season>
            <volume>1</volume>
            <issue>2</issue>
            <fpage>104</fpage>
            <page-range>104-11</page-range>
            <pub-id pub-id-type="pmid">20061816</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18291.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wing</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Monoclonal antibody first dose cytokine release syndromes-mechanisms and prediction.</article-title>
            <source>J Immunotoxicol</source>
            <year>2008</year>
            <month>Jan</month>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-5</page-range>
            <pub-id pub-id-type="pmid">18382853</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18291.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Browne</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Holland</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Immunodeficiency secondary to anticytokine autoantibodies.</article-title>
            <source>Curr Opin Allergy Clin Immunol</source>
            <year>2010</year>
            <month>Dec</month>
            <volume>10</volume>
            <issue>6</issue>
            <fpage>534</fpage>
            <page-range>534-41</page-range>
            <pub-id pub-id-type="pmid">20966748</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18291.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wallis</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Infectious complications of tumor necrosis factor blockade.</article-title>
            <source>Curr Opin Infect Dis</source>
            <year>2009</year>
            <month>Aug</month>
            <volume>22</volume>
            <issue>4</issue>
            <fpage>403</fpage>
            <page-range>403-9</page-range>
            <pub-id pub-id-type="pmid">19491672</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18291.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bowie</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Enns</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Flint</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fitzgerald</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary actinomycosis complicating infliximab therapy for Crohn disease.</article-title>
            <source>BMJ Case Rep</source>
            <year>2009</year>
            <volume>2009</volume>
            <pub-id pub-id-type="pmid">21686384</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18291.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaur</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mahl</surname>
                <given-names>TC</given-names>
              </name>
            </person-group>
            <article-title>Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases.</article-title>
            <source>Dig Dis Sci</source>
            <year>2007</year>
            <month>Jun</month>
            <volume>52</volume>
            <issue>6</issue>
            <fpage>1481</fpage>
            <page-range>1481-4</page-range>
            <pub-id pub-id-type="pmid">17429728</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18291.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kelesidis</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Salhotra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fleisher</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Uslan</surname>
                <given-names>DZ</given-names>
              </name>
            </person-group>
            <article-title>Listeria endocarditis in a patient with psoriatic arthritis on infliximab: are biologic agents as treatment for inflammatory arthritis increasing the incidence of Listeria infections?</article-title>
            <source>J Infect</source>
            <year>2010</year>
            <month>May</month>
            <volume>60</volume>
            <issue>5</issue>
            <fpage>386</fpage>
            <page-range>386-96</page-range>
            <pub-id pub-id-type="pmid">20176052</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18291.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Le Saux</surname>
                <given-names>N</given-names>
              </name>
              <collab>Canadian Paediatric Society, Infectious Diseases and Immunization Committee</collab>
            </person-group>
            <article-title>Biologic response modifiers to decrease inflammation: Focus on infection risks.</article-title>
            <source>Paediatr Child Health</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>17</volume>
            <issue>3</issue>
            <fpage>147</fpage>
            <page-range>147-54</page-range>
            <pub-id pub-id-type="pmid">23449972</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18291.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Christensen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tanjong Ghogomu</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Maxwell</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Macdonald</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Filippini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Skoetz</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Francis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lopes</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Guyatt</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Schmitt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>La Mantia</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Weberschock</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Roos</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Siebert</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hershan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lunn</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Tugwell</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Buchbinder</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Adverse effects of biologics: a network meta-analysis and Cochrane overview.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2011</year>
            <month>Feb</month>
            <day>16</day>
            <volume>2011</volume>
            <issue>2</issue>
            <fpage>CD008794</fpage>
            <pub-id pub-id-type="pmid">21328309</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18291.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sakai</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Nanki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Koike</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yamazaki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nagasawa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Amano</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sumida</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ihata</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yasuda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nakajima</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sugihara</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tamura</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fujii</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dobashi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Miura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Miyasaka</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Harigai</surname>
                <given-names>M</given-names>
              </name>
              <collab>REAL study group</collab>
            </person-group>
            <article-title>The risk of serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors decreased over time: a report from the registry of Japanese rheumatoid arthritis patients on biologics for long-term safety (REAL) database.</article-title>
            <source>Rheumatol Int</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>34</volume>
            <issue>12</issue>
            <fpage>1729</fpage>
            <page-range>1729-36</page-range>
            <pub-id pub-id-type="pmid">24852650</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18291.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fouque-Aubert</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jette-Paulin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Combescure</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Basch</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tebib</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gossec</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebo-controlled trials.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>69</volume>
            <issue>10</issue>
            <fpage>1756</fpage>
            <page-range>1756-61</page-range>
            <pub-id pub-id-type="pmid">19640854</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18291.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lebrec</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ponce</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Preston</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Iles</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Born</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Hooper</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Tumor necrosis factor, tumor necrosis factor inhibition, and cancer risk.</article-title>
            <source>Curr Med Res Opin</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>31</volume>
            <issue>3</issue>
            <fpage>557</fpage>
            <page-range>557-74</page-range>
            <pub-id pub-id-type="pmid">25651481</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18291.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perez-Alvarez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>P&#x000e9;rez-de-Lis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ramos-Casals</surname>
                <given-names>M</given-names>
              </name>
              <collab>BIOGEAS study group</collab>
            </person-group>
            <article-title>Biologics-induced autoimmune diseases.</article-title>
            <source>Curr Opin Rheumatol</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>25</volume>
            <issue>1</issue>
            <fpage>56</fpage>
            <page-range>56-64</page-range>
            <pub-id pub-id-type="pmid">23114587</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18291.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Toussirot</surname>
                <given-names>&#x000c9;</given-names>
              </name>
              <name>
                <surname>Houvenagel</surname>
                <given-names>&#x000c9;</given-names>
              </name>
              <name>
                <surname>Go&#x000eb;b</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Fouache</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Le Dantec</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dernis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wendling</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ansemant</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Berthelot</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Bader-Meunier</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kantelip</surname>
                <given-names>B</given-names>
              </name>
              <collab>Le CRI</collab>
            </person-group>
            <article-title>Development of inflammatory bowel disease during anti-TNF-&#x003b1; therapy for inflammatory rheumatic disease: a nationwide series.</article-title>
            <source>Joint Bone Spine</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>79</volume>
            <issue>5</issue>
            <fpage>457</fpage>
            <page-range>457-63</page-range>
            <pub-id pub-id-type="pmid">22088934</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18291.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nagy</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Luk&#x000e1;cs</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sziray</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fazekas</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Flori&#x000e1;n</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tam&#x000e1;si</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>K&#x000e1;rolyi</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>[Adverse events during biological therapy -- focusing on dermatological side-effects].</article-title>
            <source>Orv Hetil</source>
            <year>2011</year>
            <month>Feb</month>
            <day>06</day>
            <volume>152</volume>
            <issue>6</issue>
            <fpage>212</fpage>
            <page-range>212-20</page-range>
            <pub-id pub-id-type="pmid">21278026</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18291.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Joyau</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Veyrac</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dixneuf</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Jolliet</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect?</article-title>
            <source>Clin Exp Rheumatol</source>
            <year>2012</year>
            <season>Sep-Oct</season>
            <volume>30</volume>
            <issue>5</issue>
            <fpage>700</fpage>
            <page-range>700-6</page-range>
            <pub-id pub-id-type="pmid">22935567</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18291.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matsumoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Miura</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Momoyama</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>New-onset multiple sclerosis associated with adalimumab treatment in rheumatoid arthritis: a case report and literature review.</article-title>
            <source>Clin Rheumatol</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>32</volume>
            <issue>2</issue>
            <fpage>271</fpage>
            <page-range>271-5</page-range>
            <pub-id pub-id-type="pmid">23149905</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18291.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kerbleski</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Gottlieb</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>Dermatological complications and safety of anti-TNF treatments.</article-title>
            <source>Gut</source>
            <year>2009</year>
            <month>Aug</month>
            <volume>58</volume>
            <issue>8</issue>
            <fpage>1033</fpage>
            <page-range>1033-9</page-range>
            <pub-id pub-id-type="pmid">19592682</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18291.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Otani</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Levin</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Banerji</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous Manifestations of Reactions to Biologics.</article-title>
            <source>Curr Allergy Asthma Rep</source>
            <year>2018</year>
            <month>Feb</month>
            <day>21</day>
            <volume>18</volume>
            <issue>2</issue>
            <fpage>12</fpage>
            <pub-id pub-id-type="pmid">29464437</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18291.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uzel</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Orange</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Poliak</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Marciano</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Heller</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Holland</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Complications of tumor necrosis factor-&#x003b1; blockade in chronic granulomatous disease-related colitis.</article-title>
            <source>Clin Infect Dis</source>
            <year>2010</year>
            <month>Dec</month>
            <day>15</day>
            <volume>51</volume>
            <issue>12</issue>
            <fpage>1429</fpage>
            <page-range>1429-34</page-range>
            <pub-id pub-id-type="pmid">21058909</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18291.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kwon</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Cot&#x000e9;</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Cuffe</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Kramer</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Case reports of heart failure after therapy with a tumor necrosis factor antagonist.</article-title>
            <source>Ann Intern Med</source>
            <year>2003</year>
            <month>May</month>
            <day>20</day>
            <volume>138</volume>
            <issue>10</issue>
            <fpage>807</fpage>
            <page-range>807-11</page-range>
            <pub-id pub-id-type="pmid">12755552</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18291.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pham-Huy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sadarangani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ostensen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Castillo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Troster</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Vaudry</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Top</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>From mother to baby: antenatal exposure to monoclonal antibody biologics.</article-title>
            <source>Expert Rev Clin Immunol</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>15</volume>
            <issue>3</issue>
            <fpage>221</fpage>
            <page-range>221-229</page-range>
            <pub-id pub-id-type="pmid">30570400</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18291.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carmona</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>G&#x000f3;mez-Reino</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez-Valverde</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Montero</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pascual-G&#x000f3;mez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mola</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Carre&#x000f1;o</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Figueroa</surname>
                <given-names>M</given-names>
              </name>
              <collab>BIOBADASER Group</collab>
            </person-group>
            <article-title>Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.</article-title>
            <source>Arthritis Rheum</source>
            <year>2005</year>
            <month>Jun</month>
            <volume>52</volume>
            <issue>6</issue>
            <fpage>1766</fpage>
            <page-range>1766-72</page-range>
            <pub-id pub-id-type="pmid">15934089</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18291.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hanson</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Gannon</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Khamo</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sodhi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Orr</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Stubbings</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Improvement in safety monitoring of biologic response modifiers after the implementation of clinical care guidelines by a specialty.</article-title>
            <source>J Manag Care Pharm</source>
            <year>2013</year>
            <season>Jan-Feb</season>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>49</fpage>
            <page-range>49-67</page-range>
            <pub-id pub-id-type="pmid">23383700</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18291.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cush</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Biological drug use: US perspectives on indications and monitoring.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2005</year>
            <month>Nov</month>
            <volume>64 Suppl 4</volume>
            <issue>Suppl 4</issue>
            <fpage>iv18</fpage>
            <page-range>iv18-23</page-range>
            <pub-id pub-id-type="pmid">16239379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18291.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Del Olmo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hern&#x000e1;ndez</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Galindo-Izquierdo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>T&#x000e9;bar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Balsa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carmona</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>[Peri-operative management of disease modifying anti-rheumatic drugs: recommendations based on a meta-analysis].</article-title>
            <source>Rev Esp Cir Ortop Traumatol</source>
            <year>2012</year>
            <season>Sep-Oct</season>
            <volume>56</volume>
            <issue>5</issue>
            <fpage>393</fpage>
            <page-range>393-412</page-range>
            <pub-id pub-id-type="pmid">23594897</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18291.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gribble</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Sivakumar</surname>
                <given-names>PV</given-names>
              </name>
              <name>
                <surname>Ponce</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>SD</given-names>
              </name>
            </person-group>
            <article-title>Toxicity as a result of immunostimulation by biologics.</article-title>
            <source>Expert Opin Drug Metab Toxicol</source>
            <year>2007</year>
            <month>Apr</month>
            <volume>3</volume>
            <issue>2</issue>
            <fpage>209</fpage>
            <page-range>209-34</page-range>
            <pub-id pub-id-type="pmid">17428152</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
